What's new

Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised

Mar 25, 2025 - 16:56
 0
Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of re...

Next Article

Building performance standards set to proliferate, evolve in 2025

Related Posts

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Tarceva, erlotinib, Date of authorisation: 19/09/2005, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0

Agenda of the CHMP meeting 24-27 March 2025

Mar 24, 2025  0